ALCAM and colorectal carcinoma: Our group suggested that the identification of ALCAM/CD166 as a molecule mediating the docking and uptake of these TEVs could be potentially exploited to block the peritoneal metastasis cascade promoted by TEVs in CRC and OvC patients [94].